NeuroSense Therapeutics Statistics
Total Valuation
NRSN has a market cap or net worth of $24.71 million. The enterprise value is $21.40 million.
Important Dates
The next estimated earnings date is Monday, June 23, 2025, before market open.
| Earnings Date | Jun 23, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
NRSN has 23.99 million shares outstanding. The number of shares has increased by 36.38% in one year.
| Current Share Class | 23.99M |
| Shares Outstanding | 23.99M |
| Shares Change (YoY) | +36.38% |
| Shares Change (QoQ) | +12.72% |
| Owned by Insiders (%) | 50.29% |
| Owned by Institutions (%) | 2.77% |
| Float | 11.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 9.26 |
| P/TBV Ratio | 9.57 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.21, with a Debt / Equity ratio of 0.03.
| Current Ratio | 2.21 |
| Quick Ratio | 1.78 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -2,478.16% and return on invested capital (ROIC) is -1,191.29%.
| Return on Equity (ROE) | -2,478.16% |
| Return on Assets (ROA) | -159.50% |
| Return on Invested Capital (ROIC) | -1,191.29% |
| Return on Capital Employed (ROCE) | -383.35% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$600,588 |
| Employee Count | 17 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -18.25% in the last 52 weeks. The beta is 1.35, so NRSN's price volatility has been higher than the market average.
| Beta (5Y) | 1.35 |
| 52-Week Price Change | -18.25% |
| 50-Day Moving Average | 1.05 |
| 200-Day Moving Average | 1.06 |
| Relative Strength Index (RSI) | 52.33 |
| Average Volume (20 Days) | 111,137 |
Short Selling Information
The latest short interest is 200,177, so 0.83% of the outstanding shares have been sold short.
| Short Interest | 200,177 |
| Short Previous Month | 290,875 |
| Short % of Shares Out | 0.83% |
| Short % of Float | 1.68% |
| Short Ratio (days to cover) | 1.27 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -9.90M |
| Pretax Income | -10.11M |
| Net Income | -10.21M |
| EBITDA | -9.88M |
| EBIT | -9.90M |
| Earnings Per Share (EPS) | -$0.55 |
Full Income StatementBalance Sheet
The company has $3.38 million in cash and $73,000 in debt, giving a net cash position of $3.31 million or $0.14 per share.
| Cash & Cash Equivalents | 3.38M |
| Total Debt | 73,000 |
| Net Cash | 3.31M |
| Net Cash Per Share | $0.14 |
| Equity (Book Value) | 2.58M |
| Book Value Per Share | 0.11 |
| Working Capital | 2.41M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$10.14 million and capital expenditures -$3,000, giving a free cash flow of -$10.14 million.
| Operating Cash Flow | -10.14M |
| Capital Expenditures | -3,000 |
| Free Cash Flow | -10.14M |
| FCF Per Share | -$0.42 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |